Is NCT07049926 recruiting in Nashville, TN?

Yes, NCT07049926 is currently recruiting participants at its Nashville, TN location. This renal cell carcinoma clinical trial is actively enrolling qualified participants.

How do I join the renal cell carcinoma clinical trial in Nashville?

To join this clinical trial in Nashville, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Nashville clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Renal Cell Carcinoma Clinical Trial in Nashville, TN

About This Renal Cell Carcinoma Study in Nashville

Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-\[L\]1) adjuvant therapy. This substudy will

Sponsor: Merck Sharp & Dohme LLC

Who Can Participate

Inclusion Criteria

include but are not limited to the following:

Has a histologically confirmed diagnosis of unresectable locally advanced/metastatic renal cell carcinoma (RCC) with clear cell component

Has received no other prior systemic therapy for treatment of advanced/metastatic clear cell renal cell carcinoma (ccRCC) except for adjuvant programmed cell death ligand 1 (PD-(L)1) therapy

Has disease recurrence during adjuvant anti- PD-(L)1 therapy or ≤24 months following the last dose of adjuvant anti-PD-(L)1 therapy

Is able to swallow oral medication

Submits an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated

Participants receiving bone resorptive therapy (must have therapy initiated at least 2 weeks before allocation/randomization)

Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤140/90 mm Hg with no change in antihypertensive medications within 1 week before allocation/randomization

Has adequate organ function The main

Exclusion Criteria

include but are not limited to the following:

Has clinically significant hematuria, hematemesis, or hemoptysis of (\>2.5 mL) of red blood, or other history of significant bleeding

Has clinically significant cardiovascular disease within 12 months from first dose of study intervention

Has deep vein thrombosis within 3 months before allocation/randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before allocation/randomization

Has history of idiopathic pulmonary fibrosis, organizing pneumonia, or evidence of active pneumonitis

Has serious wound, ulcer or bone fracture or has had major surgery within 8 weeks before first dose of study intervention

Has symptomatic pleural effusion (for example cough, dyspnea, pleuritic chest pain), ascites, or pericardial fluid requiring drainage in the last 4 weeks before allocation/randomization

Has gastrointestinal (GI) disorders, including those associated with a high risk of perforation or fistula formation

Has malabsorption due to prior GI surgery or GI disease

Has moderate to severe hepatic impairment

Has received colony-stimulating factors within 28 days prior to intervention allocation/randomization

Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids

Is currently receiving strong inhibitors of cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of the study

Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention

Is currently receiving anticoagulants or platelet inhibitors that cannot be discontinued for the duration of the study

Have been previously allocated/randomized to study intervention in any sub study of protocol MK-3475-U03

Has a known additional malignancy that is progressing or has required active treatment within the past 3 years

Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis

Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation

Has active autoimmune disease that has required systemic treatment in the past 2 years

Has an active infection requiring systemic therapy

Has history of human immunodeficiency virus (HIV) infection

Has hepatitis B or hepatitis C virus infection

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT07049926) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Renal Cell Carcinoma Treatment Options in Nashville, TN

If you're searching for renal cell carcinoma treatment options in Nashville, TN, this clinical trial (NCT07049926) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced renal cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all renal cell carcinoma clinical trials near you to find additional studies recruiting in your area.

Renal Cell Carcinoma Clinical Trial in Nashville, TN

Expert Care in Nashville

IRB Approved

No-Cost Care

Apply for This Nashville Location

Why Participate?

Simple Process